Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer

Abstract

The epithelial-mesenchymal transition (EMT) and angiogenesis have emerged as two pivotal events in cancer progression. Curcumin has been extensively studied in preclinical models and clinical trials of cancer prevention due to its favorable toxicity profile. However, the possible involvement of curcumin in the EMT and angiogenesis in lung cancer remains unclear. This study found that curcumin inhibited hepatocyte growth factor (HGF)-induced migration and EMT-related morphological changes in A549 and PC-9 cells. Moreover, pretreatment with curcumin blocked HGF-induced c-Met phosphorylation and downstream activation of Akt, mTOR, and S6. These effects mimicked that of c-Met inhibitor SU11274 or PI3 kinase inhibitor LY294002 or mTOR inhibitor rapamycin treatment. c-Met gene overexpression analysis further demonstrated that curcumin suppressed lung cancer cell EMT by inhibiting c-Met/Akt/mTOR signaling pathways. In human umbilical vein endothelial cells (HUVECs), we found that curcumin also significantly inhibited PI3K/Akt/mTOR signaling and induced apoptosis and reduced migration and tube formation of HGF-treated HUVEC. Finally, in the experimental mouse model, we showed that curcumin inhibited HGF-stimulated tumor growth and induced an increase in E-cadherin expression and a decrease in vimentin, CD34, and vascular endothelial growth factor (VEGF) expression. Collectively, these findings indicated that curcumin could inhibit HGF-promoted EMT and angiogenesis by targeting c-Met and blocking PI3K/Akt/mTOR pathways.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 51

1. 1.

   Iwatsuki, M, Mimori, K, Yokobori, T, Ishi, H, Beppu, T, Nakamori, S et al. (2010 ). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293–299.

   Not in our library10.1111/j.1349-7006.2009.01419.x

2. 2.

   Meng, F and Wu, G (2012 ). The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev 31: 455–467.

   Not in our library10.1007/s10555-012-9379-3

3. 3.

   Gao, D, Vahdat, LT, Wong, S, Chang, JC and Mittal, V (2012 ). Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72: 4883–4889.

   Not in our library10.1158/0008-5472.can-12-1223

4. 4.

   Gentile, A, Trusolino, L and Comoglio, PM (2008 ). The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85–94.

   Not in our library10.1007/s10555-007-9107-6

5. 5.

   Feng, Y, Minca, EC, Lanigan, C, Liu, A, Zhang, W, Yin, L et al. (2014 ). High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. J Thorac Oncol 9: 646–653.

   Not in our library10.1097/jto.0000000000000145

6. 6.

   Umeguchi, H, Sueoka-Aragane, N, Kobayashi, N, Nakamura, T, Sato, A, Takeda, Y et al. (2015 ). Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep 33: 391–396.

   Not in our library10.3892/or.2014.3560

7. 7.

   Keedy, VL and Sandler, AB (2007 ). Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98: 1825–1830.

   Not in our library10.1111/j.1349-7006.2007.00620.x

8. 8.

   Bohonowych, JE, Gopal, U and Isaacs, JS (2010 ). Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010: 412985.

   Not in our library10.1155/2010/412985

9. 9.

   Trusolino, L and Comoglio, PM (2002 ). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289–300.

   Not in our library10.1038/nrc779

10. 10.

    Graupera, M and Potente, M (2013 ). Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res 319: 1348–1355.

    Not in our library10.1016/j.yexcr.2013.02.021

11. 11.

    Eder, JP, Vande Woude, GF, Boerner, SA and LoRusso, PM (2009 ). Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207–2214.

    Not in our library10.1158/1078-0432.ccr-08-1306

12. 12.

    Chen, Q, Wang, Y, Xu, K, Lu, G, Ying, Z, Wu, L et al. (2010 ). Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol Rep 23: 397–403.

    Not in our library

13. 13.

    Li, L, Braiteh, FS and Kurzrock, R (2005 ). Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104: 1322–1331.

    Not in our library10.1002/cncr.21300

14. 14.

    Kim, SY, Jung, SH and Kim, HS (2005 ). Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem Biophys Res Commun 337: 510–516.

    Not in our library10.1016/j.bbrc.2005.09.079

15. 15.

    Singh, M and Singh, N (2011 ). Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem 347: 1–11.

    Not in our library10.1007/s11010-010-0606-3

16. 16.

    Yu, T, Li, J, Qiu, Y and Sun, H (2012 ). 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation. Mol Cell Biochem 361: 47–54.

    Not in our library10.1007/s11010-011-1086-9

17. 17.

    Chen, QY, Shi, JG, Yao, QH, Jiao, DM, Wang, YY, Hu, HZ et al. (2012 ). Lysosomal membrane permeabilization is involved in curcumin-induced apoptosis of A549 lung carcinoma cells. Mol Cell Biochem 359: 389–398.

    Not in our library10.1007/s11010-011-1033-9

18. 18.

    Ji, C, Cao, C, Lu, S, Kivlin, R, Amaral, A, Kouttab, N et al. (2008 ). Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol 62: 857–865.

    Not in our library10.1007/s00280-007-0674-6

19. 19.

    Lin, SS, Lai, KC, Hsu, SC, Yang, JS, Kuo, CL, Lin, JP et al. (2009 ). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett 285: 127–133.

    Not in our library10.1016/j.canlet.2009.04.037

20. 20.

    Chen, QY, Zheng, Y, Jiao, DM, Chen, FY, Hu, HZ, Wu, YQ et al. (2014 ). Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J Nutr Biochem 25: 177–185.

    Not in our library10.1016/j.jnutbio.2013.10.004

21. 21.

    Chen, QY, Jiao, DM, Wang, LF, Wang, L, Hu, HZ, Song, J et al. (2015 ). Curcumin inhibits proliferation-migration of NSCLC by steering crosstalk between a Wnt signaling pathway and an adherens junction via EGR-1. Mol Biosyst 11: 859–868.

    Not in our library10.1039/c4mb00336e

22. 22.

    Chen, HW, Lee, JY, Huang, JY, Wang, CC, Chen, WJ, Su, SF et al. (2008 ). Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 68: 7428–7438.

    Not in our library10.1158/0008-5472.can-07-6734

23. 23.

    Huang, T, Chen, Z and Fang, L (2013 ). Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells. Oncol Rep 29: 117–124.

    Not in our library10.3892/or.2012.2080

24. 24.

    Chen, WC, Lai, YA, Lin, YC, Ma, JW, Huang, LF, Yang, NS et al. (2013 ). Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 61: 11817–11824.

    Not in our library10.1021/jf404092f

25. 25.

    Gururaj, AE, Belakavadi, M, Venkatesh, DA, Marmé, D and Salimath, BP (2002 ). Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 297: 934–942.

    Not in our library10.1016/s0006-291x(02)02306-9

26. 26.

    Perry, MC, Demeule, M, Régina, A, Moumdjian, R and Béliveau, R (2010 ). Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 54: 1192–1201.

    Not in our library10.1002/mnfr.200900277

27. 27.

    Nagai, T, Arao, T, Furuta, K, Sakai, K, Kudo, K, Kaneda, H et al. (2011 ). Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10: 169–177.

    Not in our library10.1158/1535-7163.mct-10-0544

28. 28.

    Matsumoto, K and Nakamura, T (2006 ). Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119: 477–483.

    Not in our library10.1002/ijc.21808

29. 29.

    Chang, L, Graham, PH, Hao, J, Ni, J, Bucci, J, Cozzi, PJ et al. (2013 ). Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4: e875.

    Not in our library10.1038/cddis.2013.407

30. 30.

    Zhang, YW, Su, Y, Volpert, OV and Vande Woude, GF (2003 ). Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100: 12718–12723.

    Not in our library10.1073/pnas.2135113100

31. 31.

    Usatyuk, PV, Fu, P, Mohan, V, Epshtein, Y, Jacobson, JR, Gomez-Cambronero, J et al. (2014 ). Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem 289: 13476–13491.

    Not in our library10.1074/jbc.m113.527556

32. 32.

    Masago, K, Togashi, Y, Fujita, S, Sakamori, Y, Okuda, C, Kim, YH et al. (2012 ). Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Med Oncol 29: 1614–1621.

    Not in our library10.1007/s12032-011-0009-7

33. 33.

    Bharti, A, Ma, PC, Maulik, G, Singh, R, Khan, E, Skarin, AT et al. (2004 ). Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24(2C): 1031–1038.

    Not in our library

34. 34.

    Thiery, JP and Sleeman, JP (2006 ). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131–142.

    Not in our library10.1038/nrm1835

35. 35.

    Elliott, BE, Hung, WL, Boag, AH and Tuck, AB (2002 ). The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 80: 91–102.

    Not in our library10.1139/y02-010

36. 36.

    Whittaker, S, Marais, R and Zhu, AX (2010 ). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989–5005.

    Not in our library10.1038/onc.2010.236

37. 37.

    Sun, LN, Chen, ZX, Liu, XC, Liu, HY, Guan, GJ and Liu, G (2014 ). Curcumin ameliorates epithelial-to-mesenchymal transition of podocytes in vivo and in vitro via regulating caveolin-1. Biomed Pharmacother 68: 1079–1088.

    Not in our library10.1016/j.biopha.2014.10.005

38. 38.

    Peruzzi, B and Bottaro, DP (2006 ). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657–3660.

    Not in our library10.1158/1078-0432.ccr-06-0818

39. 39.

    Sun, XD, Liu, XE and Huang, DS (2013 ). Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep 29: 2401–2407.

    Not in our library10.3892/or.2013.2385

40. 40.

    Ponzo, MG, Lesurf, R, Petkiewicz, S, O’Malley, FP, Pinnaduwage, D, Andrulis, IL et al. (2009 ). Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 106: 12903–12908.

    Not in our library10.1073/pnas.0810402106

Cited by papers we hold 3

• The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges · 2019
  No notice
• Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy · 2019
  No notice
• Sirtuins, a promising target in slowing down the ageing process · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.